Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality®▼ (galcanezumab): New packaging

Changes to the galcanezumab pre-filled pen carton and packaging materials occurred in August 2020. Slight changes to the carton size, carton closure and the location of the carton graphics were implemented.

Further information

The tamper evident seal was removed and replaced by a glue dot.

The orientation of the information contained on the label and Instructions for Use was slightly changed. It might not be noticeable to the user.1

Lock ring position

The lock ring position on the pre-filled pen should be in the locked position when a new carton is first opened and the pre-filled pen is first removed from the carton. There are multiple checks in the manufacturing process to ensure the lock ring is in the locked position during assembly and labeling.1

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: September 30, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question